Clinical and Functional Consequences of C-Terminal Variants in MCT8: A Case Series

Abstract

Context Genetic variants in SLC16A2, encoding the thyroid hormone transporter MCT8, can cause intellectual and motor disability and abnormal serum thyroid function tests, known as MCT8 deficiency. The C-terminal domain of MCT8 is poorly conserved, which complicates predicting the deleteriousness of variants in this region. We studied the functional consequences of five novel variants within this domain and their relation to the clinical phenotypes. Methods We enrolled male subjects with intellectual disability in whom genetic variants were identified in exon 6 of SLC16A2. The impact of identified variants was evaluated in transiently transfected cell lines and patient-derived fibroblasts. Results Seven individuals from 5 families harboured potentially deleterious variants affecting the C-terminal domain of MCT8. Two boys with clinical features considered atypical for MCT8 deficiency, had a missense variant (c.1724A>G;p.(His575Arg) or c.1796A>G;p.(Asn599Ser)) that did not affect MCT8 function in transfected cells or patient-derived fibroblasts, challenging a causal relationship. Two brothers with classical MCT8 deficiency had a truncating c.1695delT;p.(Val566*) variant that completely inactivated MCT8 in vitro. The three other boys had relatively less severe clinical features and harboured frameshift variants that elongate the MCT8 protein (c.1805delT;p.(Leu602HisfsTer680) and c.del1826-1835;p.(Pro609GlnfsTer676)) and retained ~50% residual activity. Additional truncating variants within transmembrane domain 12 were fully inactivating, whereas those within the intracellular C-terminal tail were tolerated. Conclusions Variants affecting the intracellular C-terminal tail of MCT8 are likely benign unless they cause frameshifts that elongate the MCT8 protein. These findings provide clinical guidance in the assessment of the pathogenicity of variants within the C-terminal domain of MCT8.

Monocarboxylate Transporter 8 Deficiency: From Pathophysiological Understanding to Therapy Development

“…MCT8 Deficiency: From Pathophysiology to Therapy phenotype (59). Additional studies are warranted to further delineate the relationship between the different mutations and the phenotypic variability.…”

“…Evaluation of residual thyroid hormone transport capacity of these variants in in vitro systems or patient-derived fibroblasts is therefore indispensable to confirm the pathogenic nature of identified variants ( 56 – 58 ). Recent studies suggested that C-terminal missense variants beyond amino acid residue Met574 (long isoform) are well-tolerated and likely to not results in a phenotype ( 59 ). Additional studies are warranted to further delineate the relationship between the different mutations and the phenotypic variability.…”

Identification of A Novel Hemizygous SLC16A2 Nonsense Mutation in Allen-Herndon-Dudley Syndrome

“…The thyroid profile in our patient is consistent with the literature. More than 80 different mutations of SLC16A2 gene have been described from over 100 families to date (9). The identified mutations of the SLC16A2 gene include causing splice site mutations, deletions or insertions of one or more codons, nonsense mutations causing a premature truncation of the MCT8 protein and missense mutations leading to 1-amino-acid substitutions (10).…”